This trial is testing a new cancer treatment for men with metastatic castration resistant prostate cancer. It is a 1:1:1 randomized open-label multicenter phase II study, which means that patients will be randomly assigned to one of three different treatment groups. The study will take place at multiple centers, and patients will be observed over the course of the trial.
1 Primary · 9 Secondary · Reporting Duration: Up to 2 years
Active Control
70 Total Participants · 4 Treatment Groups
Primary Treatment: Arm III: Abiraterone + Prednisone + Olaparib · No Placebo Group · Phase 2
Age 18+ · Male Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: